Company Overview and News
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (96-0)
According to a new report published by Allied Market Research, titled, "Idiopathic Pulmonary Fibrosis Market by Type of Drug: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global idiopathic pulmonary fibrosis market was valued at $1,616 million in 2016, and is projected to reach $3,569 million by 2023, growing at a CAGR of 11.9% from 2017 to 2023. Perifenidone held more than half share of the total market in 2016. (78-0)
Given that the Royal Swedish Academy of Sciences Sveriges Riksbank Prize in Economic Sciences went to Richard Thaler yesterday, I thought it might be timely to access the transcript of our MIB interview from 2015. You can also stream it above, or listen on iTunes and Bloomberg. (6-0)
With a positive press release today regarding its flagship drug Humira suggesting it can avoid US biosimilar competition until 2023, ABBV trades at 22X TTM GAAP EPS. (215-0)
- At the highest dose level, 5 out of 6 patients (83%) reached an improvement of at least 50% in atopic dermatitis symptoms (EASI-50) by week 4 (6-0)
GILD has strong assets in HIV/AIDS and HCV, but can it get revalued as a growth stock again? (20-0)
In this weekly series, I present a few ideas from scans for reader discussion and further due diligence. (16-8)
Appreciating EUR/USD continues to drag down portfolio and dividend values with Gifted Working Time crossing the 2-week mark.
With earnings season drawing to a close, focus is back on pipeline and regulatory updates. While Regeneron Pharmaceuticals (REGN - Free Report) , which has several pipeline catalysts lined up for the second half of the year, reported data on one of its late-stage pipeline candidates, Gilead Sciences (GILD - Free Report) got priority review for its investigational HIV treatment. Recap of the Week’s Most Important Stories Regeneron Shelves RSV Antibody on Study Failure: Regeneron’s investigational antibody, suptavumab (REGN2222), for respiratory syncytial virus (RSV), failed to meet the primary endpoint in a late-stage study conducted in infants.
Authorities in Ecuador have detained the crew of a Chinese fishing boat suspected to have caught endangered sharks in the Galapagos Islands.
Additionally, we are selling out one position with catalysts that are farther out in order to purchase shares in an idea with more immediate upside potential.
Important new data on novel idiopathic pulmonary fibrosis candidates look set to continue to emerge in the wake of two encouraging reports in the past couple of weeks. Biogen (NASDAQ:BIIB), Promedior, Sanofi (NYSE:SNY) and Roche (OTCQX:RHHBY) are all due to unveil fresh information from mid-stage candidates before the end of the year.
Welcome to another edition of "3 Things in Biotech You Should Learn Today," a daily digest dedicated to helping you mine recent news in the biotech and pharma industries!
Welcome to your weekly roundup of EP Vantage's snippets - short takes on smaller news items.
There are a few competitors in the space, but the market opportunity is still big enough for many.
Two promising positions are let go of (for now) and relegated to the Contenders List. I will keep a close eye on them.
Webcast presentation of the results to be held tomorrow 10 August, 14.00 CET/8 AM EDT, +32 2 404 0659, access code 2084135; more call number info further down
Investors are always looking for stocks that are poised to beat at earnings season and Galapagos NV (GLPG - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Galapagos is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for GLPG in this report.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has shined bright within the biotech industry this year. VRTX stock has more than doubled over the past 12 months. That stands in stark contrast to the sector, which in general has struggled due to high valuations and political uncertainty regarding healthcare reform.
Quanta Services, Inc. (PWR - Free Report) is slated to report second-quarter 2017 results before the opening bell on Aug 3.
GoPro, Inc. (GPRO - Free Report) is slated to release second-quarter 2017 results, after the closing bell on Aug 3.
Match Group, Inc. (MTCH - Free Report) is set to report second-quarter 2017 earnings results on Aug 1.
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) reported second-quarter 2017 earnings per share of 10 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 6 cents. Notably, the company had posted a loss of 1 cent in the year-ago quarter. Strong product revenues led to higher profits in the quarter.
The Biotechnology sector remains one of the top performing sectors this year with the benchmark Nasdaq Biotechnology Index, as represented by ETF (IBB), gaining 17% in the first-half. The index though still remains ~29% down from its all-time high achieved in mid-2015. In comparison, the S&P 500 (SPY) was up 8%, and the Nasdaq Composite (QQQ) up 14%, in the first-half.
We expect Flowserve Corporation (FLS - Free Report) to beat earnings when it reports second-quarter 2017 results on Jul 27, after the closing bell.
3h - Asif
18h - Asif